Skip to main content
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. — Investor Relations & Filings

Ticker · CTMX ISIN · US23284F1057 LEI · 5493004VW2FW0QLL3345 US Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-08-14 Major Shareholding Noti…
Country US United States of America
Listing US CTMX

About CytomX Therapeutics, Inc.

https://cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from CytomX Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It references a regulatory filing related to securities registration and does not contain financial statements, management discussion, or detailed report content. The document length is short (1287 characters) and is clearly a correspondence related to a regulatory filing process. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-08-14 English
Regulatory Filings 2025
Regulatory Filings
2025-08-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an update on a clinical trial (CX-2051 Phase 1 study), including safety events and regulatory reporting to the FDA. It does not contain comprehensive financial statements or detailed financial performance data. The document is not an earnings release, annual report, or interim report. It is an event-driven update about ongoing clinical trial progress and safety information, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-08-13 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.